Drug Profile


Alternative Names: PG 490

Latest Information Update: 24 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories; Fujian Institute of Medical Science; Harold C. Simmons Arthritis Research Center; National Cancer Center (Tokyo); Pharmagenesis; Stanford University; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Diterpenes; Epoxy compounds; Phenanthrenes
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Inflammation; Rheumatoid arthritis; Solid tumours; Transplant rejection

Most Recent Events

  • 13 Jun 2002 A preclinical study has been added to the Cancer pharmacodynamics section
  • 18 Apr 2002 No development reported - Preclinical for Inflammation in China (unspecified route)
  • 18 Apr 2002 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top